SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Clara Barton — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientClara Barton
Date of birth1821-12-25
IdentifiersMRN HR-NI024-SYN-TD; SSN (made up) 000-24-3357
Document date1874-03-03
AuthorEleanor Whitcombe, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-week depression treatment review. [S]

History of Present Illness

Ms. Barton returns six weeks after starting sertraline 50 mg. She has had four sessions of cognitive behavioral therapy and has kept a daily plan of small tasks and walks. She went back to work three weeks ago on a 25-hour week and has kept to it. Her mood is a little better on most days and she can concentrate on one report at a time, but she still feels flat, tires by mid-afternoon, and sleeps about five and a half hours. She has had no side effects since the first week and has missed no doses. She has had no suicidal thoughts. She has seen two friends each week. [S]

ElementDetail
Interval changeSomewhat better mood and concentration; still flat and tired
PsychotherapyFour CBT sessions; daily activity plan
WorkBack three weeks on a 25-hour week
SleepAbout five and a half hours
SafetyNo suicidal thoughts
PHQ-912, down from 18

Review of Systems

SystemResultFinding
ConstitutionalPositiveTires by mid-afternoon; appetite improving; weight up 0.6 kg
GastrointestinalNegativeNo nausea, diarrhea, or bleeding
PsychiatricPositiveMood flat but improving; no suicidal thoughts, elevated mood, or racing thoughts

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Sertraline 50 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morningOral route1874-01-20 to 1874-03-03completedS
Sertraline 100 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morningOral route1874-03-03activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1874-03-03Body height152cmS
1874-03-03Body weight50.2kgS
1874-03-03Body mass index (BMI) [Ratio]21.7kg/m2S
1874-03-03Systolic blood pressure120mm[Hg]S
1874-03-03Diastolic blood pressure76mm[Hg]S
1874-03-03Heart rate76/minS
1874-03-03Respiratory rate14/minS
1874-03-03Body temperature36.6CelS
1874-03-03Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1874-03-03Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]12{score}S

Physical Exam

Vital signs recorded on 1874-03-03; see the Vital Signs section. [S]

SystemFinding
GeneralNeatly dressed; more animated than at intake
Mental statusAlert; speech normal in rate; mood "better, but not myself"; affect mildly constricted and reactive; thought process linear; no suicidal ideation; insight and judgment good

Problems

ProblemClinical statusVerificationCodeProvenance
Major depressive disorder, recurrent, moderate (moderately severe symptoms at intake), after a prolonged humanitarian deployment; synthetic modern diagnosis linked to her documented periods of depression and nervous prostrationactiveconfirmed F33.1S — Synthetic modern diagnosis. Her periods of depression and nervous prostration are documented in her own words (D); calling them major depression is a retrospective interpretation (R), and no diagnosis was made in her lifetime.
Occupational burnout after eighteen months leading field medical relief in a war zoneactiveconfirmed Z73.0S — Synthetic contributing factor echoing her documented exhaustion after wartime relief work; burnout is an occupational phenomenon, not a mental disorder.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyPHQ-9Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuationCompleted today12, down 33 percent from 18: partial response; dose increased
SurveySuicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9)Every visit during active treatmentCompleted todayNo suicidal thoughts, intent, plan, or behavior since the last visit; PHQ-9 item 9 scored 0. Protective factors unchanged; safety plan reviewed
Medication safetyAdherence and adverse-effect reviewEvery visit during active treatmentCompleted todayNo missed doses; no side effects since the first week
Medication safetyTolerability check two weeks after the dose increase2 weeks after each dose changeDueNurse telephone check booked for two weeks from today
Self-managementPsychotherapy, activity, sleep, work hours, and social contactEvery visit during active treatmentCompleted todayFour CBT sessions; 25-hour week; sleep about five and a half hours; friends twice a week
LaboratoryLithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS)Only on those drugsNot indicatedTreated with an SSRI only

Goal progress:

Guideline basis: VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Nurse telephone check in two weeks; depression review in six weeks. Next scheduled visit 1874-04-14: twelve-week depression treatment review. [S]